BML Pharma

Manhasset, United States Founded: 1996 • Age: 30 yrs Acquired By Endo International
Small molecule therapeutics for cancer and inflammatory diseases were developed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About BML Pharma

BML Pharma is a company based in Manhasset (United States) founded in 1996 was acquired by Endo International in July 2002. BML Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.

  • Headquarter Manhasset, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Endo International

    (Jul 29, 2002)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of BML Pharma

Premium access

Detailed funding history for BML Pharma

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in BML Pharma

BML Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Endo International.

All
Institutional
Investor Description Founded Year Domain Location
Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines
Locked Locked Locked
Premium access

Investor details for BML Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by BML Pharma

Investments
Premium access

Investment portfolio details for BML Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - BML Pharma

Premium access

Detailed financials for BML Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Bml Pharma Comparisons

BML Pharma Primary company
Description
Small molecule therapeutics for cancer and inflammatory dise...
Location
Manhasset, United States
Founded Year
1996
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for BML Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of BML Pharma

BML Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
MicroRNA-based therapeutics are developed for treating multiple diseases.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Locked Locked Locked
Therapeutics for cancer and rare diseases are developed.
Premium access

Detailed competitors of BML Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Bml Pharma

Premium access

Complete news archive for BML Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about BML Pharma

BML Pharma was founded in 1996.

BML Pharma is headquartered in Manhasset, United States. It is registered at Manhasset, New York, United States.

BML Pharma was founded in 1996 in Manhasset, United States, as a late clinical-stage company in the biotechnology sector. Small molecule therapeutics were developed by the firm for cancer treatment, infectious diseases, and inflammatory conditions. A lead candidate, Immunol, an oral rinse for oral mucositis in cancer patients, reached Phase III trials. The company was acquired by Endo Pharmaceuticals in 2002 for 14 million in upfront cash.

BML Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

BML Pharma has 1 investor. Key investors include Endo International.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available